���沙莫瑞林历史与监管定位 — Quick Reference

By Editorial Desk · published 2025-12-03 · last reviewed 2026-01-05 · Faq

Everything below concerns Visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

特沙莫瑞林历史与监管定位

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

Background and Clinical Development

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

Tesamorelin at a glance

Background And Regulatory Development

Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Related pages on this site

• Durable dataset
• Clear collection
• Structured digest
• Adaptive toolkit
• Professional toolkit
• Clear primer
• Optimized summary
• Professional digest

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Background and Pharmacology of Tesamorelin

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.

Further detail

The Mediterranean coast was well known to the Carthaginians. Their close relations with Phoenician-Punic settlements and shared cultural ties likely gave them considerable political and economic influence there from the 6th or 5th century BC, alongside the establishment of unequal treaties with Iberian city-states. After Carthage's defeat by Rome in the First Punic War, it sought new western territories, culminating in the Barcid conquest of the Iberian Peninsula in 237 BC. The Romans invaded the Iberian Peninsula in 218 BC and expelled the Carthaginians after the Battle of Ilipa in 206 BC. Within 200 years, mainland Portugal had been annexed by the Romans despite resistance from local tribes such as the Lusitanians under the leadership of Viriathus and other leaders. In 409, with the decline of the Western Roman Empire, the Iberian Peninsula was invaded by Germanic tribes. Western Iberia was integrated into the Suebian Kingdom, with its capital in or near Braga. The Visigoths defeated the Suebi in 585 and ruled the peninsula until the early 8th century. In 711, the Iberian Peninsula was invaded from the south by the Umayyad Caliphate, which expanded rapidly. By 716, present-day mainland Portugal was part of the Muslim Iberian territories known as al-Andalus.

== Pharmacokinetics == The human oral bioavailability is approximately 50% and maximum plasma concentration was achieved within 1–2 hours after dosing. Emedastine is mainly metabolized by the liver. There are two primary metabolites: 5-hydroxyemedastine and 6-hydroxyemedastine. They are excreted in the urine as both free and conjugated forms. The 5'-oxoanalogs of 5-hydroxyemedastine, 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites. The elimination half-life of oral emedastine in plasma is 3–4 hours, whereas that of topical emedastine is 10 hours. Approximately 44% of the oral dose is recovered in the urine over 24 hours with only 3.6% of the dose excreted as parent drug.

Overall, poneratoxin disrupts normal function of voltage-gated sodium channels in both vertebrates and invertebrates. It causes repetitive firing and prolongation of action potentials, particularly in the central nervous system of insects. The increase in signaling is what causes the intense pain from bullet ant stings. Poneratoxin is in an inactive state when stored in the ant venom reservoir due to the reservoir's acidic conditions, but it becomes toxic when activated via a multistep process. The combination of poneratoxin binding to a cell membrane (in order to act upon a voltage-gated sodium channel) and the movement from acidic conditions in the ant venom reservoir to basic conditions at the target site leads to poneratoxin undergoing a conformational change that activates it. Catterall et al. hypothesized that some polypeptide neurotoxins modify voltage-gated channels function via a "voltage-sensor trapping" mechanism. The hypothesis states that neurotoxins similar to poneratoxin, such as alpha-scorpion toxins, act upon sodium channels via binding to the channels' receptor site 3, which normally affects the channels' ability to inactivate. Therefore, receptor site 3 neurotoxins often affect sodium channels by slowing or blocking inactivation. Normally, the region of the channel where neurotoxin receptor site 3 is undergoes a conformational change of an outward movement to lead to inactivation. Receptor site 3 neurotoxins are proposed to prevent this conformational change via interaction with acidic and hydrophobic amino acid residues at that site.

increases from −0.32 V in uranium, through 0.34 V (Np) and 1.04 V (Pu) to 1.34 V in americium revealing the increasing reduction ability of the An4+ ion from americium to uranium. All actinides form AnH3 hydrides of black color with salt-like properties. Actinides also produce carbides with the general formula of AnC or AnC2 (U2C3 for uranium) as well as sulfides An2S3 and AnS2.

==== Student loan repayments ==== Student loan repayments made by employers to their employees were temporarily tax-free to the employees but they are now permanently tax-free. The tax-free limit per year will be indexed for inflation starting in 2026.

Sources: en.wikipedia.org

Supporting material

=== Heating === In January 2023, Forbes reported that a "heating" tool allows TikTok to manually promote certain videos, comprising 1–2% of daily views. The practice began as a way to grow and diversify content and influencers that were not automatically picked up by the recommendation algorithm. It was also used to promote brands, artists, and NGOs, such as the FIFA World Cup and Taylor Swift. However, some employees have abused it to promote their own accounts or those of their spouses, while others have felt that their guidelines leave too much room for discretion. TikTok said only a few individuals can approve heating in the US and the promoted videos take up less than 0.002% of user feeds. To address concerns of Chinese influence, the company is negotiating with the Committee on Foreign Investment in the United States (CFIUS) such that future heating could only be performed by vetted security personnel in the US and the process would be audited by third-parties such as Oracle.

=== Category:EC 1.8 (act on a sulfur group of donors) === Category:EC 1.8.1 (with NAD+ or NADP+ as acceptor) Glutathione reductase EC 1.8.1.7 Thioredoxin reductase EC 1.8.1.9 Category:EC 1.8.2 (with a cytochrome as acceptor) Category:EC 1.8.3 (with oxygen as acceptor) Sulfite oxidase EC 1.8.3.1 Category:EC 1.8.4 (with a disulfide as acceptor) Category:EC 1.8.5 (with a quinone or similar compound as acceptor) Category:EC 1.8.6 deleted, included in EC 2.5.1.18 Category:EC 1.8.7 (with an iron–sulfur protein as acceptor) Category:EC 1.8.98 (with other, known, acceptors) Category:EC 1.8.99 (with other acceptors)

The thiol group from the cysteine loses a proton, so it becomes negative charged and the amino group of the histidine catches a proton, which gives it a positive charge. The cysteine makes a bond with the carbon breaking the carbon's double bond with oxygen and converting it into a simple bond. The amino group is attracted by the positive charge of the histidine and a bond between these two is formed. The peptide bond is now broken and the carbonyl group is remade. The NH2R group is released from the histidine. The bond between the thiol group from the cysteine and the carbon is broken and a NHR group replaces it. When this two bonds are broken, the catalytic triad from the chymopapain is available to be used again.

In 2013, Germany revealed the existence of their 60-person Computer Network Operation unit. The German intelligence agency, BND, announced it was seeking to hire 130 "hackers" for a new "cyber defence station" unit. In March 2013, BND president Gerhard Schindler announced that his agency had observed up to five attacks a day on government authorities, thought mainly to originate in China. He confirmed the attackers had so far only accessed data and expressed concern that the stolen information could be used as the basis of future sabotage attacks against arms manufacturers, telecommunications companies and government and military agencies. Shortly after Edward Snowden leaked details of the U.S. National Security Agency's cyber surveillance system, German Interior Minister Hans-Peter Friedrich announced that the BND would be given an additional budget of 100 million Euros to increase their cyber surveillance capability from 5% of total internet traffic in Germany to 20% of total traffic, the maximum amount allowed by German law.

Sources: en.wikipedia.org

Frequently asked questions